Alnylam Pharmaceuticals, a Cambridge-based biotechnology firm, has received a (Dollar) 3.2m milestone payment from GlaxoSmithKline (GSK) as part of their ongoing collaboration to utilize Alnylam's RNA interference (RNAi) technology to develop GSK's cell-culture based influenza vaccine. While almost all other viral vaccines (e.g., mumps, measles, and polio) are currently produced via cell-culture, influenza vaccines have been resistant to cell-culture based manufacturing due to insufficient ...
via Medindia Health News More READ For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/08/are-concerns-of-investor-hushed-alnylam.html
No comments:
Post a Comment